FOR IMMEDIATE RELEASE
For further information, please contact:
Tel: +1 707-588-2160
New President joins IDEX Health & Science as it segments its focus towards Analytical Instruments and InVitro Diagnostics / Biotechnology Markets
ROHNERT PARK, CA, April 7, 2015 — On March 2, 2015 IDEX Health & Science, a division of IDEX Corporation’s (NYSE:IEX) Health & Science Technologies, announced Gustavo “Gus” Salem as the new President. Gus Salem has over 25 years of extensive experience in the life science industry, including his background as President and CEO of SISCAPA Assay Technologies, and Vice President and General Manager of the Biological Systems Division at Agilent Technologies.
Salem is an established leader in mass spectrometry, analytical instruments, IVD diagnostics and consumables markets, both in regards to customers, as well as large portfolios of products. He received his undergraduate degree in Physiological Psychology from the University of California at Berkeley.
In addition to this new leadership announcement, IDEX Health & Science is pleased to report its recent segmentation into two distinct businesses: Analytical Instruments and In Vitro Diagnostics / Biotechnology. The Analytical Instruments business will serve the non-clinical analytical instrument market, while the IVD/Biotech business will serve clinical OEM instrumentation manufacturers. This realignment into two key sectors will help to reinforce a targeted marketing strategy and increase product differentiation.
IDEX Health & Science looks forward to a new phase of growth as it continues to identify opportunities to maximize its influence and expansion in fluidic, IVD and diagnostics markets. These structural changes reinforce a commitment to product innovation that will more precisely meet customers’ needs and better leverage IDEX Health & Science’s exceptional portfolio of fluidic products and applied technologies.